{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T19:06:51Z","timestamp":1694977611629},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1477-7819-8-40","type":"journal-article","created":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T18:14:43Z","timestamp":1274292883000},"source":"Crossref","is-referenced-by-count":12,"title":["Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis"],"prefix":"10.1186","volume":"8","author":[{"given":"Kazuaki","family":"Tanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Tokumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ohdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"key":"679_CR1","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24: 2137-2150. 10.1200\/JCO.2005.05.2308.","journal-title":"J Clin Oncol"},{"key":"679_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M: modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric-cancer. Cancer. 1993, 72: 37-41. 10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P.","journal-title":"Cancer"},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bjc.1995.114","volume":"71","author":"S Pyrhonen","year":"1995","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995, 71: 587-591.","journal-title":"Br J Cancer"},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-93-4-533","volume":"93","author":"JS Macdonald","year":"1980","unstructured":"Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980, 93: 533-536.","journal-title":"Ann Intern Med"},{"key":"679_CR5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a058932","volume":"5","author":"M Findlay","year":"1994","unstructured":"Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994, 5: 609-616.","journal-title":"Ann Oncol"},{"key":"679_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","volume":"21","author":"A Ohtsu","year":"2003","unstructured":"Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S, Japan Clinical Oncology Group Study (JCOG9205): Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003, 21: 54-59. 10.1200\/JCO.2003.04.130.","journal-title":"J Clin Oncol"},{"key":"679_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncology. 2009, 10: 1063-1069. 10.1016\/S1470-2045(09)70259-1.","journal-title":"Lancet Oncology"},{"key":"679_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology. 2008, 9: 215-221. 10.1016\/S1470-2045(08)70035-4.","journal-title":"Lancet Oncology"},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02993858","volume":"13","author":"AI Einzig","year":"1996","unstructured":"Einzig AI, Neuberg D, Remick SC, Karp DD, Odwyer PJ, Stewart JA, Benson AB: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol. 1996, 13: 87-93. 10.1007\/BF02993858.","journal-title":"Med Oncol"},{"key":"679_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/14796694.2.5.603","volume":"2","author":"PC Thuss-Patience","year":"2006","unstructured":"Thuss-Patience PC, Kretzschmar A, Reichardt P: Docetaxel in the treatment of gastric cancer. Future Oncol. 2006, 2: 603-620. 10.2217\/14796694.2.5.603.","journal-title":"Future Oncol"},{"key":"679_CR11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/CAD.0b013e32832ec02b","volume":"20","author":"S Fushida","year":"2009","unstructured":"Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T: Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs. 2009, 20: 752-756. 10.1097\/CAD.0b013e32832ec02b.","journal-title":"Anticancer Drugs"},{"key":"679_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00280-009-0936-6","volume":"64","author":"DY Zang","year":"2009","unstructured":"Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH: Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2009, 64: 877-883. 10.1007\/s00280-009-0936-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"679_CR13","first-page":"1843","volume":"24","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res. 2004, 24: 1843-1851.","journal-title":"Anticancer Res"},{"key":"679_CR14","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/1078-0432.CCR-05-2425","volume":"12","author":"K Yoshida","year":"2006","unstructured":"Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006, 12: 3402-3407. 10.1158\/1078-0432.CCR-05-2425.","journal-title":"Clin Cancer Res"},{"key":"679_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247. 10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003, 13: 176-181. 10.1016\/S1053-4296(03)00031-6.","journal-title":"Semin Radiat Oncol"},{"key":"679_CR17","first-page":"2602","volume":"56","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996, 56: 2602-2606.","journal-title":"Cancer Res"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000012099","volume":"58","author":"W Koizumi","year":"2000","unstructured":"Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000, 58: 191-197. 10.1159\/000012099.","journal-title":"Oncology"},{"key":"679_CR19","first-page":"693","volume":"13","author":"M Fukushima","year":"1998","unstructured":"Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S, Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998, 13: 693-698.","journal-title":"Int J Oncol"},{"key":"679_CR20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","volume":"34","author":"Y Sakata","year":"1998","unstructured":"Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998, 34: 1715-1720. 10.1016\/S0959-8049(98)00211-1.","journal-title":"Eur J Cancer"},{"key":"679_CR21","volume-title":"Gastrointestinal Cancer Symposium","author":"H Imamura","year":"2008","unstructured":"Imamura H, Iishi H, Tsuburaya A, Hatake K, Imamoto HME: Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301\/TOP-002). Gastrointestinal Cancer Symposium. 2008, Abstract #5:Orland, USA."},{"key":"679_CR22","first-page":"64","volume":"6","author":"E Van Den Neste","year":"2000","unstructured":"Neste Van Den E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H, Cazenave I, Lefresne-Soulas F, Piccart M: A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 2000, 6: 64-71.","journal-title":"Clin Cancer Res"},{"key":"679_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/ijc.21879","volume":"119","author":"Y Wada","year":"2006","unstructured":"Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006, 119: 783-791. 10.1002\/ijc.21879.","journal-title":"Int J Cancer"},{"key":"679_CR24","first-page":"2775","volume":"29","author":"Y Tsutani","year":"2009","unstructured":"Tsutani Y, Ohara M, Suzuki T, Minami K, Miyahara E, Kameda A, Noso Y: Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer. Anticancer Res. 2009, 29: 2775-2779.","journal-title":"Anticancer Res"},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10147-008-0775-1","volume":"13","author":"M Fujii","year":"2008","unstructured":"Fujii M: Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). International Journal of Clinical Oncology. 2008, 13: 201-205. 10.1007\/s10147-008-0775-1.","journal-title":"International Journal of Clinical Oncology"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-8-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1477-7819-8-40\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-8-40.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T09:36:03Z","timestamp":1548149763000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-8-40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-8-40","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,19]]},"article-number":"40"}}